BioCentury
ARTICLE | Clinical News

Isis falls on Phase II diabetes data

February 4, 2015 2:55 AM UTC

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) lost $3.97 to $64.70 on Tuesday after releasing top-line data from its Phase II trial of ISIS-PTP1BRx to treat Type II diabetes.

The company said patients treated with ISIS-PTP1BRx achieved a statistically significant mean reduction in HbA1c of 0.7 percentage points from baseline at 36 weeks, compared to 0.2 percentage points in placebo-treated patients (p=0.03). Isis did not release data for the trial's primary endpoint, which measured HbA1c reduction at 27 weeks. ...